Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLYCOM: Cevostamab Combinations in Multiple Myeloma
NCT05583617Phase 2Recruiting
- Sponsor
- Roche
- Start
- Nov 2023
- Primary completion
- Jul 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label trial of cevostamab in multiple myeloma (MM) (2 arms), sponsored by Roche. Primary endpoints: Percentage of Participants with Adverse Events at 5 years, Objective Response Rate at 5 years and 4 more. Started Nov 2023; status: recruiting.
02
Drugs
cevostamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05583617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05583617.